RBFC
NBIX icon

Roman Butler Fullerton & Co’s Neurocrine Biosciences NBIX Stock Holding History

Roman Butler Fullerton & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,837
Closed -$1.26M – 217
2023
Q4 		$1.26M Buy
+8,837
New +$1.02M 0.49% 54
2023
Q1 		– Sell
-11,864
Closed -$1.28M – 201
2022
Q4 		$1.28M Buy
11,864
+1,305
+12% +$153K 0.66% 46
2022
Q3 		$1.14M Buy
+10,559
New +$1.07M 0.72% 36
2020
Q3 		– Sell
-7,422
Closed -$905K – 159
2020
Q2 		$905K Buy
+7,422
New +$820K 0.65% 54

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Roman Butler Fullerton & Co's NBIX Position: Q1 2024 in Review

Roman Butler Fullerton & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 8,837 shares — an estimated $1.26M sold.

Roman Butler Fullerton & Co first reported a position in NBIX in Q2 2020 and held it in 4 quarters. The position peaked at $1.28M in Q4 2022. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Roman Butler Fullerton & Co reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 8,837 Neurocrine Biosciences shares in Q1 2024, an estimated $1.26M.
  • Roman Butler Fullerton & Co first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 4 quarters.
  • Roman Butler Fullerton & Co's Neurocrine Biosciences position peaked at $1.28M in Q4 2022.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Roman Butler Fullerton & Co's 13F filing for Q1 2024, filed 29 Apr 2024.